Ipamorelin PK/PD model reveals SC50 of 214 nmol/L and short 2-hour half-life in humans
Background
Growth hormone deficiency and the desire to stimulate endogenous GH secretion without the side-effect burden of exogenous GH administration has driven interest in GHSR-acting secretagogues. Ipamorelin is a selective growth hormone releasing peptide that stimulates pulsatile GH release via GHSR (the ghrelin receptor) without meaningfully elevating cortisol or prolactin — a key differentiation from older secretagogues. Despite early clinical interest, the quantitative relationship between ipamorelin plasma exposure and GH response had not been formally described through PK/PD modeling in humans. Understanding the concentration–response relationship is essential for rational dose selection and for predicting GH responses across individuals with differing receptor sensitivity or body composition.
Study Design
A dose-escalation trial enrolled eight healthy male subjects per dose level across five intravenous infusion rates — 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg — each administered over 15 minutes, yielding 40 subjects total. Serial plasma samples were collected for ipamorelin and GH concentration measurement. A population PK/PD model was fitted using an indirect response framework, with a zero-order GH release term operating over a finite duration to capture the episodic character of GH secretion. Inter-individual variability in both PK and PD parameters was estimated.
Results
Ipamorelin exhibited clean dose-proportional PK across all five infusion rates. The terminal half-life was 2 hours, clearance was 0.078 L/h/kg, and the volume of distribution at steady state was 0.22 L/kg, indicating limited tissue distribution. GH stimulation produced a single discrete pulse at every dose level, with the GH peak occurring at 0.67 hours post-infusion start, followed by an exponential decline to negligible concentrations.
The concentration required for half-maximal GH stimulation (SC50) was 214 nmol/L, and the maximal GH production rate was estimated at 694 mIU/L/h.
The indirect response model with zero-order release over finite duration successfully described the episodic GH dynamics. Inter-individual variability in PD parameters exceeded that observed for PK parameters, indicating that receptor-level or downstream signaling differences among subjects are a larger source of variability than differences in drug disposition.
Key Findings
- Ipamorelin terminal half-life: 2 hours; clearance: 0.078 L/h/kg; Vss: 0.22 L/kg
- GH peak occurred at 0.67 hours across all dose levels with exponential decline thereafter
- SC50 (half-maximal GH stimulation concentration) = 214 nmol/L
- Maximal GH production rate estimated at 694 mIU/L/h by indirect response model
- PD inter-individual variability exceeded PK variability across all dose levels
Why It Matters
The quantified SC50 of 214 nmol/L gives clinicians and researchers a concrete pharmacological benchmark for designing ipamorelin dosing regimens — doses that push plasma concentrations well above this threshold should approach maximal GH stimulation, while sub-threshold exposures will produce proportionally blunted responses. The short 2-hour half-life means that the GH-stimulating window closes rapidly, reinforcing the utility of timed dosing relative to sleep or training windows. High inter-individual PD variability signals that population-average dosing will be a poor fit for a meaningful fraction of users, and that biomarker-guided titration (measuring actual GH pulse amplitude) may be warranted in clinical protocols. The validated PK/PD model framework also enables simulation of alternative routes, dose intervals, or combination strategies with GHRH analogues to engineer more sustained GH elevations.
